Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor

Abstract—Tumor suppressor in lung cancer-1 (TSLC1) loss is common in many human cancers, including meningioma. In this study, we demonstrate that TSLC1 protein and RNA expression is lost in 60% to 65% of high-grade gliomas, and that TSLC1 reintroduction into glioma cells results in growth suppression. Moreover, Tslc1 loss in mice results in increased astrocyte proliferation in vivo and in vitro. These data indicate that TSLC1 functions as a glioma tumor suppressor.

S.S. Houshmandi, PhD; E.I. Surace, PhD; H.B. Zhang, MD, PhD; G.N. Fuller, MD, PhD; and D.H. Gutmann, MD, PhD

Recent advances in molecular genetics have led to the identification of novel genes involved in brain tumor pathogenesis. In this regard, tumor suppressor in lung cancer-1 (TSLC1), originally identified as a non–small-cell lung cancer tumor suppressor,1 is involved in the pathogenesis of diverse types of human cancers,2,3 including meningioma.4 TSLC1 is expressed in human leptomeninges but is lost or markedly reduced in 30% of World Health Organization (WHO) Grade I meningiomas.4 In normal rodent tissues, Tslc1 messenger RNA (mRNA) is likewise expressed in astrocytes,5 raising the possibility that TSLC1 might also be important in the molecular pathogenesis of astrocytoma. In this study, we demonstrate loss or marked reduction of TSLC1 expression in high-grade astrocytoma (glioma) at both the protein and RNA levels. Consistent with its role as a tumor suppressor, reintroduction of TSLC1 in TSLC1-deficient glioma cells results in growth suppression. Moreover, Tslc1 loss in genetically engineered mice results in increased astrocyte proliferation in vivo and in vitro.

Methods. Patient samples. The glioma tissue microarray (TMA) was assembled at the MD Anderson Cancer Center (G.N.F.) as previously described.6 Additional tumor samples were obtained from the Washington University/Siteman Cancer Center Tumor Tissue Repository. Human tissues were used in accordance with approved human studies protocols.

Immunohistochemistry. TSLC1 antibody (ES1; 1:20,000 dilution) and Vectastain ABC development (Vector Laboratories, Burlingame, CA) were used for immunohistochemical analysis.

Western blots. Samples were lyzed in NP-40 lysis buffer with protease inhibitors, and proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis before Western blot analysis with TSLC1 (ES1; 1:2,000 dilution), S6 (Cell Signaling Technology, Beverly, MD; 1:2,000 dilution), and α-tubulin (Sigma, St. Louis MO; 1:10,000 dilution) antibodies. Densitometric analysis was performed using the Gel-Pro Analyzer 4.0 (MediaCybernetics, Silver Spring, MD) with α-tubulin or S6 as a loading control.

Real-time reverse-transcription PCR. Complementary DNAs (cDNAs) were prepared from 1 μg of total RNA. Real-time reverse-transcription (RT) PCR was performed and analyzed as previously described.7

Clonogenic assays. 105-107 glioblastoma cells per well were transfected with 2 μg of pcDNA3.hyg or pcDNA3.hyr.gTSLC1 plasmid DNA using Lipofectamine reagent (Invitrogen, Carlsbad, CA) before selection with Hygromycin B (200 μg/mL; Roche Diagnostics, Indianapolis, IN) for 14 to 21 days. Surviving colonies were stained with crystal violet and counted.

Immunofluorescence. One-week-old Tslc1+/− mice. Tslc1+/− mice were generated at the J. David Gladstone Institute (University of California, San Francisco) from BayGenomics XI486 embryonic stem cells.8

Thymidine incorporation assay. Primary astrocyte cultures were generated from 3-day-old WT and Tslc1+/− mouse brains as previously described,2 and seeded at 5 × 10⁶ cells per well for 24 hours of serum starvation. [3H]-thymidine (1 μCi per well) was added in serum-free media, and the counts per minute were determined after 24 hours.

Results. Immunohistochemical analysis denoted no loss of TSLC1 expression in 26 WHO Grade I and 6 Grade II gliomas. In contrast, 60% of the WHO Grade III gliomas and 65% of the WHO Grade IV (glioblastoma or GBM) glioma samples showed loss of TSLC1 expression (figure 1, A and B). TSLC1 loss was more common in astrocytic neoplasms; most oligodendrogliomas retained TSLC1 expression (42/46; 91%). Because frozen specimens from these TMA tumors were not available, GBM samples from an independent set of 25 patients were examined for TSLC1 expression at both protein and the mRNA levels. Western blotting and densitometric analysis demonstrated more than a twofold reduction in TSLC1 expression in 15 tumors (60%), with 8 tumors showing more than a fourfold reduction (32%; representative data shown in figure 1B). The remaining tumors demon-
strated less than twofold decreases in TSLC1 expression. To determine whether TSLC1 loss was observed at the RNA level, we examined TSLC1 mRNA expression by real-time RT-PCR using TSLC1-specific primers in the same samples examined by Western blot. We observed a similar pattern of TSLC1 mRNA loss in these GBM specimens (data not shown). There was an 84% concordance between TSLC1 protein and TSLC1 RNA loss in these tumors. Last, no TSLC1 expression was observed in a panel of both human and rodent high-grade glioma cell lines (figure 1C).

Previous studies from our laboratory and others have shown that TSLC1 functions as a negative growth regulator (tumor suppressor) when reintroduced into TSLC1-deficient tumor cells.4,10 We used clonogenic assays on the TSLC1-deficient human U87 glioblastoma cell line to assess TSLC1 growth suppression. TSLC1 re-expression resulted in a twofold reduction in the number of hygromycin-resistant U87 colonies compared with vector-transfected cells (figure 2).

Because TSLC1 loss is not the only genetic change in high-grade glioma, we sought to determine whether Tslc1 loss in mice was sufficient to confer an astrocyte growth advantage in vivo and in vitro. Recent studies from our laboratory have shown that mice heterozygous for an inactivating Tslc1 gene mutation exhibit >90% reduction in Tslc1 expression in the brain and in derivative astrocytes (figure 3B). To determine the effect of Tslc1 expression on astrocyte proliferation in vivo, WT and Tslc1−/− mice were injected with BrdU and analyzed by immunofluorescence with BrdU and GFAP antibodies. We observed a twofold increase in both BrdU-positive and GFAP-positive cells in the hippocampus of Tslc1−/− mice compared with WT littermates (figure 3A). Similar increases in BrdU-positive and GFAP-positive cells were observed in other brain regions (e.g., neocortex) of Tslc1−/− mice (data not shown).

Because not all of the proliferating BrdU-positive cells colabeled with GFAP, we next sought to directly measure the effect of reduced Tslc1 expression on astrocyte proliferation in vitro. Using [3H]-thymidine incorporation, we observed a twofold increase in proliferation in Tslc1−/− astrocytes relative to WT astrocytes (figure 3B). Collectively, these results provide direct evidence that TSLC1 functions as an astrocyte growth regulator.

### Table 1: Malignancy Grade and % TSLC1 Loss

<table>
<thead>
<tr>
<th>Malignancy Grade</th>
<th>% TSLC1 Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO I</td>
<td>0 (0/26)</td>
</tr>
<tr>
<td>WHO II</td>
<td>0 (0/5)</td>
</tr>
<tr>
<td>WHO III</td>
<td>60 (24/40)</td>
</tr>
<tr>
<td>WHO IV</td>
<td>65 (44/68)</td>
</tr>
</tbody>
</table>

Figure 1. TSLC1 expression in glioma. (A) TSLC1 immunohistochemistry was performed on gliomas representing each World Health Organization (WHO) malignancy grade. Whereas no loss of TSLC1 expression was observed in WHO Grade I and II gliomas, anaplastic astrocytoma (WHO III) and glioblastoma (WHO IV) exhibited 60% to 65% loss of TSLC1 expression. (B) Representative immunohistochemical results from one TSLC1-immunopositive (TSLC1+) and one TSLC1-immunonegative (TSLC1−) WHO IV glioma (left panel) are shown. Magnification = 20×. Also included is a representative Western blot of TSLC1 expression in two human glioblastoma (GBM) tumor samples (right panel), demonstrating both retention and loss of TSLC1 protein expression. (C) Western blot analysis of TSLC1 expression in several glioma cell lines, including rat C6, mouse CT-2A and DBT (top panel), human U118, U138, U87, and U373 (middle panel), and human SF126, SF129, and SF188 (bottom panel) cells, demonstrates loss of TSLC1 protein expression in all cell lines. Normal mouse astrocytes (WT) were included as a positive control for TSLC1 expression. α-Tubulin was used as an internal control for equal protein loading.

Figure 2. TSLC1 re-expression results in reduced glioma growth. U87 cells transfected in triplicate with either an empty vector or a vector containing human TSLC1 were selected in hygromycin, and the number of colonies was determined after 2 to 3 weeks. A representative plate from each transfection is shown. The number of colonies in the TSLC1-transfected U87 cells was significantly reduced relative to empty vector. * p < 0.003, unpaired t test.
Discussion. In this report, we demonstrate TSLC1 loss at the protein and RNA levels in high-grade (WHO III/IV) glioma but not in low-grade WHO I or II glial neoplasms. These findings suggest that TSLC1 is most likely associated with malignant progression, rather than glioma formation. Similar to our previous findings in meningioma, TSLC1 loss predominated in high-grade tumors with high proliferative indices. Interestingly, TSLC1 loss was not observed in another glial cell tumor (oligodendroglioma), which may reflect a unique role for TSLC1 in astrocyte growth control.

Because genomic alterations involving chromosome 11q23 are rare in glioma, as is true for meningioma, the mechanism of TSLC1 gene inactivation likely involves epigenetic silencing (e.g., promoter methylation). Future studies will be required to determine whether methylation accounts for the reduced TSLC1 expression observed in glioma.

Consistent with the function of TSLC1 as a negative growth regulator, we show that the TSLC1 suppresses human glioma growth in vitro and mouse astrocyte proliferation in vivo and in vitro. These latter data demonstrate a direct effect of Tslc1 on astrocyte proliferation and suggest that TSLC1 modulates pathways important for glial cell growth. Studies are ongoing to define the mechanism of TSLC1 growth regulation in the brain.

Acknowledgment
The authors thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO, for use of the Tissue Procurement Core, which provided the GBM tumor specimens.

References


Exploded drawing in posterior cortical atrophy

Paul McMonagle, MRCPI, MD; and Andrew Kertesz, MD, FRCPC, London, Ontario, Canada

A 69-year-old woman was referred with a progressive 2-year history of problems reading, locating items in front of her, and knocking over things she reached for. Examination revealed normal acuity and visual fields, slowness directing voluntary saccades (oculomotor apraxia), and mis-reaching toward visual targets (optic ataxia). Her drawing (figure, A) was grossly distorted but cognition was otherwise normal.

Drawing tasks may be underutilized in dementia assessment but this patient’s exploded drawing illustrates the inability to perceive and bind elements of a scene together, characteristic of simultanagnosia. The progressive Balint’s syndrome, preservation of memory, and scan findings (figure, B) suggest the diagnosis of posterior cortical atrophy, which often has underlying Alzheimer pathology.

Copyright © 2006 by AAN Enterprises, Inc.

